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Abstract	
Analysis	of	blood	phenylalanine	is	central	to	the	monitoring	of	patients	with	phenylketonuria	(PKU)	
and	age-related	phenylalanine	target	treatment-ranges	(0-12	years;	120–360µmol/L,	and	>12	years;	
120-600µmol/L)	 are	 recommended	 in	 order	 to	 prevent	 adverse	 neurological	 outcomes.	 These	
target	 treatment-ranges	are	based	upon	plasma	phenylalanine	concentrations.	However,	patients	
are	 routinely	 monitored	 using	 dried	 bloodspot	 (DBS)	 specimens	 due	 to	 the	 convenience	 of	
collection.	Significant	differences	exist	between	phenylalanine	concentrations	 in	plasma	and	DBS,	
with	 phenylalanine	 concentrations	 in	 DBS	 specimens	 analysed	 by	 flow-injection	 analysis	 tandem	
mass	spectrometry	 (FIA-MS/MS)	reported	to	be	18-28%	 lower	than	paired	plasma	concentrations	
analysed	 using	 ion-exchange	 chromatography	 (IEC).	 DBS	 specimens	 with	 phenylalanine	
concentrations	 of	 360µmol/L	 and	 600µmol/L,	 at	 the	 critical	 upper-target	 treatment-range	
thresholds	 would	 be	 plasma	 equivalents	 of	 461µmol/L	 and	 768µmol/L	 respectively,	 when	 a	
reported	difference	of	28%	is	taken	into	account.	Furthermore,	analytical	test	imprecision	and	bias	
in	conjunction	with	pre-analytical	factors	such	as	volume	and	quality	of	blood	applied	to	filter	paper	
collection	devices	 to	produce	DBS	 specimens	affect	 the	 final	 test	 results.	Reporting	of	 inaccurate	
patient	 results	 when	 comparing	 DBS	 results	 to	 target	 treatment-ranges	 based	 on	 plasma	
concentrations,	 together	 with	 inter-laboratory	 imprecision	 could	 have	 a	 significant	 impact	 on	
patient	 management	 resulting	 in	 inappropriate	 dietary	 change	 and	 potentially	 adverse	 patient	
outcomes.	This	review	is	intended	to	provide	perspective	on	the	issues	related	to	the	measurement	
of	phenylalanine	in	blood	specimens	and	to	provide	direction	for	the	future	needs	of	PKU	patients	
to	ensure	reliable	monitoring	of	metabolic	control	using	the	target	treatment-ranges.		
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Synopsis	 -	 Utility	 of	 the	 target	 treatment-ranges	 for	 monitoring	 patients	 with	 Phenylketonuria	
(PKU)	 is	 limited	 by	 pre-analytical	 factors	 and	 the	 analytical	 performance	 of	 existing	 laboratory	
assays	for	blood	phenylalanine.	 	
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Introduction	
Patients	with	Phenylketonuria	(PKU)	(OMIM	#261600)	are	managed	by	the	use	of	a	phenylalanine	
restricted	 diet	 (in	 conjunction	 with	 protein	 substitute	 supplements)	 to	 lower	 the	 blood	
phenylalanine	concentrations	and	prevent	 the	adverse	neurological	 sequelae	 (Scriver	et	al	2001).	
Several	 guidelines	 for	 the	 diagnosis	 and	management	 of	 patients	with	 PKU	have	 been	 published	
over	the	years	(Smith	1993;	Wappner	et	al	1999;	Vockley	et	al	2014;	Singh	et	al	2014;	van	Spronsen	
et	al	2017).	One	of	the	key	recommendations	is	the	monitoring	of	the	phenylalanine	restricted	diet,	
using	 appropriate	 age-related	 phenylalanine	 target	 treatment-ranges	 to	 prevent	 the	 adverse	
neurological	outcomes.	In	the	latest	set	of	guidelines	(van	Spronsen	et	al	2017),	the	following	target	
treatment-ranges	 are	 recommended;	 120-360µmol/L	 for	 individuals	 aged	 0-12	 years	 and	 120-
600µmol/L	 for	 individuals	 older	 than	 12	 years.	 It	 should	 be	 noted	 that	 the	 grade	 of	
recommendation	 for	 these	 target	 ranges	 is	 graded	 as	 category	 D	 (case	 series	 reports	 &	 expert	
opinions).		Optimal	target	ranges	have	also	been	recommended	for	women	trying	to	conceive	and	
during	pregnancy	(120-360µmol/L).	An	 infant	born	to	a	PKU	mother	who	is	not	achieving	optimal	
control	can	result	in	neurological	deficits,	microcephaly	and	congenital	heart	defects.	Accurate	and	
reproducible	 monitoring	 of	 blood	 phenylalanine	 concentrations	 is	 therefore	 critical	 to	 the	
management	of	PKU.	This	 review	 is	 intended	 to	provide	perspective	on	 the	 issues	 related	 to	 the	
measurement	of	phenylalanine	in	blood	specimens	and	to	provide	direction	for	the	future	needs	of	
PKU	patients	in	terms	of	accurate	monitoring	of	metabolic	control.	With	the	evidence	presented	in	
this	 review,	 both	 laboratory	 scientists	 and	 clinicians	 should	 consider	 whether	 the	 analytical	
performance	of	 the	methods	routinely	used	 in	 their	 laboratory	 is	adequate	to	support	 the	use	of	
the	recommended	patient	target	treatment-ranges	in	the	management	of	patients	with	PKU.		
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Laboratory	methods	used	to	measure	blood	phenylalanine	
Traditionally,	the	standard	method	for	the	 laboratory	diagnosis	and	monitoring	of	PKU	patients	 is	
by	quantifying	phenylalanine	in	deproteinised	plasma	samples,	using	ion	exchange	chromatography	
(IEC)	with	ninhydrin	detection.	Whilst	this	method	is	reproducible,	it	has	a	long	analytical	run	time	
(~2	 hours	 per	 sample),	 low	 sample	 throughput	 and	 lacks	 specificity	 in	 comparison	 with	 liquid	
chromatography	 tandem	 mass	 spectrometry	 (LC-MS/MS).	 These	 limitations	 are	 reflected	 in	 the	
number	of	laboratories	moving	away	from	IEC	to	LC-MS/MS	in	recent	years	(Carling	2018a).	
Irrespective	 of	 technique,	 the	 measurement	 of	 plasma	 amino	 acids	 can	 be	 performed	 with	
reasonable	precision,	with	a	typical	 intra-laboratory	coefficient	of	variation	(CV)	for	phenylalanine	
being	approximately	5%.	The	CV	is	a	measure	of	the	variability	of	the	test	results	and	is	the	ratio	of	
the	 standard	deviation	 (SD)	 to	 the	mean	of	 the	 results	 obtained	multiplied	by	 100	 (i.e.	 CV	 (%)	 =	
SD/mean	x	100).	As	expected,	the	inter-laboratory	variation	is	greater,	as	shown	by	data	from	the	
European	Research	Network	in	Inherited	Metabolic	Diseases	(ERNDIM)	Quantitative	Plasma	Amino	
Acids	 External	 Quality	 Assessment	 (EQA)	 scheme,	 with	 an	 average	 CV	 of	 9.5%,	 at	 a	 nominal	
concentration	of	355µmol/L	(n=282	participants),	and	this	can	be	attributed	predominantly	to	the	
variation	 in	 the	 test	 standardisation,	 compounded	 by	 differences	 in	 laboratory	 practice	 (Carling	
2018b).	 Generally,	 an	 aqueous	 calibrator	 is	 used	 to	 standardise	 the	 test	 and	 these	 tend	 to	 be	
produced	 in-house,	 although	 an	 increasing	number	of	 laboratories	 now	use	 a	 certified	 reference	
material	 (CRM),	 to	 standardise	assays;	 the	Sigma	TraceCert	 solution	and	 the	National	 Institute	of	
Standards	&	 Technology	 (NIST)	 SRM2389a	 solution,	 both	 of	which	 are	 available	 commercially.	 It	
should	 be	 noted	 that	 these	 certified	 reference	materials	 (CRM)	 are	 aqueous	 solutions	 of	 amino	
acids	and	not	matrix	(plasma)	matched.	
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Plasma	 amino	 acid	 analysis	 is	 impractical	 for	 routine	monitoring	 of	metabolic	 control	 due	 to	 the	
logistics	required	in	collecting	a	venous	blood	specimen	twice	weekly	to	monthly	(depending	on	age	
and	 clinical	 need)	 from	 every	 patient,	 including	 very	 young	 children.	 Plasma	 amino	 acid	 analysis	
undertaken	in	this	way	has	been	used	primarily	for	diagnosis	and	clinical	situations,	in	which	a	full	
profile	of	amino	acids	 is	 informative,	e.g.	complete	nutritional	assessment.	 Instead,	measurement	
of	phenylalanine	in	dried	bloodspot	(DBS)	specimens	is	widely	favoured	due	to	the	convenience	of	
collecting	blood	from	a	finger-prick	onto	filter	paper	in	the	patient’s	home	and	mailing	the	sample	
directly	 to	 the	 laboratory.	Monitoring	patients	using	DBS	has	been	routinely	done	by	a	variety	of	
methods	since	the	inception	of	screening	for	PKU.	Methods	used	include:	bacterial	inhibition	assay,	
fluorimetry,	IEC,	high	performance	liquid	chromatography	(HPLC)	and	enzymatic	analysis	(Belton	et	
al	1973;	Rudy	et	al	1987;	Rohr	et	al	1996;	Wendel	et	al	1991).	During	the	last	25	years	flow-injection	
analysis	 tandem	 mass-spectrometry	 (FIA-MS/MS)	 has	 been	 used	 to	 analyse	 DBS	 for	 patient	
monitoring,	 following	 the	 introduction	 of	 this	 technology	 for	 routine	 newborn	 screening	 of	 PKU	
(Chace	 et	 al	 1993).	 Measurement	 by	 FIA-MS/MS	 has	 a	 shorter	 analysis	 time	 and	 high	 sample	
throughput;	results	can	therefore	be	communicated	to	patients	in	a	timely	manner	allowing	prompt	
dietary	adjustment.		
FIA-MS/MS	 is	 inherently	 limited	 by	 lack	 of	 specificity	 as	 analytes	 are	 not	 separated	
chromatographically.	Instead,	specificity	is	achieved	by	multiple	reaction	monitoring,	which	allows	
rapid	and	continuous	monitoring	of	 the	 specific	daughter	 ions	 relating	 to	 the	analyte	of	 interest,	
hence	 any	 isobaric	 compound	 with	 a	 common	 daughter	 ion	 has	 the	 potential	 to	 interfere	 e.g.	
benzocaine	 (anaesthetic	 agent	 found	 in	 some	 antiseptic	wipes	which	may	 be	 used	 to	 clean	 skin	
prior	 to	 sample	 collection)	 (Williams	 et	 al	 2015),	 lorazepam	 and	 omeprazole	
(https://massbank.eu/MassBank/).	 When	 these	 assays	 were	 originally	 established,	 FIA-MS/MS	
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proved	 to	 be	 a	 robust	 assay	 with	 rapid	 throughput	 (1.5	 minutes	 per	 sample)	 and	 adequate	
sensitivity	and	specificity.	We	established	a	snapshot	of	current	FIA-MS/MS	analytical	performance	
by	 circulating	 a	 commercially	 available	 DBS	 QC	material	 to	 16	 UK	 laboratories.	 The	mean	 value	
obtained	 was	 174µmol/L	 (range	 100	 to	 256µmol/L)	 with	 an	 inter-laboratory	 CV	 of	 20.2%.	 The	
assigned	 target-value	 of	 the	material	 (167µmol/L)	 also	 highlighted	 the	 large	 biases	 displayed	 by	
individual	laboratories,	which	ranged	from	-40%	to	+53%.		Technology	has	evolved	in	recent	years	
and	modern	mass-spectrometers	now	have	the	ability	to	scan	faster.	These	changes,	in	conjunction	
with	 the	 introduction	 of	 ultra	 performance	 liquid	 chromatography,	 mean	 that	 laboratories	 now	
have	the	capability	to	routinely	analyse	phenylalanine	in	DBS	with	superior	specificity	and	precision,	
and	with	a	comparable	analysis	time	and	robustness.		
A	 further	 limitation	 to	 the	 utility	 of	 DBS	 specimens	 for	 monitoring	 patients	 is	 the	 lack	 of	 a	
commercially	 available	 CRM	 for	 DBS	 amino	 acids	 on	which	 to	 standardise	 laboratory	 tests.	 As	 a	
result,	DBS	calibrators	tend	to	be	produced	in-house	by	collecting	blood	from	a	healthy	donor	and	
adding	 an	 aqueous	 phenylalanine	 enrichment	 prior	 to	 application	 onto	 filter	 paper.	 The	 exact	
preparation	of	 the	DBS	calibrator	varies	between	 laboratories	e.g.	 volume	of	blood	added	 to	 the	
filter	paper,	varying	haematocrit	of	the	specimen,	or	use	of	lysed	blood	specimens	can	all	affect	the	
measured	concentration	(George	&	Moat	2016;	Lawson	et	al	2016;	Mei	et	al	2001;	Hall	et	al	2015).	
More	 importantly,	 the	method	 used	 to	 assign	 DBS	 calibrator	 values	 can	 influence	 the	 analytical	
result.	 	
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Derivation	 of	 the	 target	 treatment-ranges	 for	 ‘blood’	 phenylalanine	 and	 the	
differences	between	DBS	and	plasma	phenylalanine	results	
It	should	be	recognised	that	the	vast	proportion	of	studies	evaluating	the	neurological	outcomes	in	
patients	with	PKU,	are	mostly	based	upon	plasma	phenylalanine	concentrations	(Vockley	et	al	2014;	
Stroup	et	al	2016;	Van	Spronsen	et	al	2017)	and	these	studies	form	the	basis	of	the	recommended	
target	 treatment-ranges.	 However,	 these	 guidelines	 refer	 to	 the	 monitoring	 of	 ‘blood’	
phenylalanine	 concentrations,	but	do	not	make	any	distinction	between	 the	 two	 specimen	 types	
(Smith	1993;	Wappner	et	al	1999;	Vockley	et	al	2014;	Singh	et	al	2014),	or	 refer	 to	 the	observed	
differences,	but	then	do	not	provide	guidance	as	to	the	most	appropriate	specimen	type	to	be	used	
(van	 Spronsen	 et	 al	 2017).	 This	 is	 disconcerting	 in	 that	 there	 are	 significant	 differences	 between	
plasma	 phenylalanine	 measured	 by	 IEC	 and	 DBS	 phenylalanine	 measured	 by	 FIA-MS/MS,	 with	
concentrations	in	DBS	being	up	to	18-28%	lower	(Table	1).		The	difference	between	DBS	and	plasma	
phenylalanine	 concentrations	 is	 reduced	 from	 -28%	 to	 -15%	 when	 both	 plasma	 and	 DBS	 are	
analysed	using	IEC	(Stroup	et	al	2016).	Furthermore,	the	difference	between	liquid	whole	blood	and	
plasma	phenylalanine	 concentrations	 is	 ~8%	when	measured	 by	 the	 same	 laboratory	 technology	
(Table	1).	These	findings	suggest	that	the	reported	differences	between	plasma	and	DBS	specimens	
are	 due	 to	 several	 factors;	 distribution	 of	 phenylalanine	 between	 plasma	 and	 erythrocytes,	
extraction	efficiency	of	phenylalanine	 from	DBS	and	 laboratory	 instrument	 test	biases.	Using	DBS	
collected	by	trained	healthcare	professionals,	we	observed	that	DBS	phenylalanine	concentrations	
measured	with	FIA-MS/MS	are	18%	lower	relative	to	the	paired	plasma	concentrations	measured	
by	 IEC	 (Figure	 1),	which	 is	 similar	 to	 those	 reported	 previously.	 The	 negative	 bias	 of	 18%	 in	 our	
laboratory	is	reproducible	and	stable	over	a	long	period	of	time.	
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The	 differences	 between	 DBS	 and	 plasma	 phenylalanine	 concentrations	 could	 have	 a	 significant	
clinical	 impact	 in	 terms	 of	management.	 For	 example;	 it	 is	 recommended	 that	 during	 pregnancy	
‘blood’	phenylalanine	concentrations	should	be	maintained	between	120	to	360µmol/L.	Assuming	
these	target	ranges	are	based	upon	plasma	concentrations,	but	the	patient	is	monitored	using	DBS	
concentrations,	 a	 DBS	 concentration	 of	 360µmol/L	 is	 equivalent	 to	 a	 plasma	 concentration	 of	
425µmol/L	 in	 our	 laboratory	 based	 upon	 current	 performance.	Whereas,	 in	 a	 laboratory	 with	 a	
negative	 bias	 of	 28%,	 DBS	 specimens	 with	 phenylalanine	 concentrations	 of	 360µmol/L	 and	
600µmol/L,	at	the	upper	critical	target	treatment-range	thresholds	would	be	plasma	equivalents	of	
461µmol/L	and	768µmol/L	respectively	(Figure	2).	
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Additional	factors	that	affect	patient	phenylalanine	test	results	
Although	the	published	patient	treatment	and	monitoring	guidelines	emphasise	the	importance	of	
biochemical	monitoring	of	phenylalanine	concentrations,	the	impact	of	the	following	factors	on	the	
final	result	reported	are	not	considered	in	any	of	the	guidelines:		
• The	 significance	 of	 the	 analytical	 test	 variation	 (imprecision)	 and	 analytical	 test	 bias	
(inaccuracy)	in	the	measurement	of	phenylalanine.	
• The	 total	 allowable	 error	 for	 a	 phenylalanine	 test	 that	 can	 be	 tolerated	 before	 it	 has	 a	
significant	impact	upon	clinical	decision	making.	
• The	impact	of	the	pre-analytical	factors	such	as	the	amount	or	volume	of	blood	applied	to	
the	filter	paper	to	produce	DBS	specimens	on	the	phenylalanine	results	obtained.	
	
Analytical	test	variation	(Imprecision)	
Laboratory	tests	are	not	perfect	and	it	 is	 imperative	that	healthcare	professionals	understand	the	
factors	that	affect	the	phenylalanine	test	results	that	they	receive	and	act	on.	A	requirement	for	the	
accreditation	 of	 clinical	 laboratories	 according	 to	 the	 International	 Standards	 Organisation	 (ISO)	
15189,	 is	 to	 provide	 the	 measurement	 of	 uncertainty	 (MU)	 for	 each	 test	 performed	 (ISO	
15189:2012).	MU	is	defined	as	the	value	that	 is	associated	with	the	test	result	 that	describes	the	
dispersion	of	values	that	could	be	obtained	for	the	test	result	due	to	the	uncertainties	arising	within	
the	test	procedure.	MU	is	calculated	using	quality	control	(QC)	specimens	analysed	in	every	batch	
of	 patient	 samples	 over	 a	 period	 of	 time	 to	 encompass	 the	 combined	 effect	 of	 all	 the	 analytical	
factors	that	influence	the	test	result	(Wayne	2012).	In	one	author’s	laboratory	(SJM)	the	mean	and	
standard	 deviation	 (SD)	 of	 a	 DBS	QC	 specimen	 analysed	 in	 166	 separate	 test	 batches	 over	 an	 8	
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month	period	using	FIA-MS/MS	was	361	(19.3)	µmol/L,	corresponding	to	an	analytical	 inter-assay	
CV	of	5.3%.	Using	these	data,	the	MU	of	the	test	can	be	calculated	using	the	following	equation:			
MU	=	SD	x	1.96.	
Using	 a	 coverage	 factor	 of	 1.96,	 there	 is	 a	 95%	 chance	 that	 the	 true	 result	 lies	 within	 a	 range	
covered	by	the	result	value	±	MU.	The	calculated	MU	for	the	DBS	phenylalanine	test	is	37.8µmol/L	
or	 10.5%.	 This	means	 that	 for	 a	DBS	 specimen	with	 a	phenylalanine	 concentration	 at	 the	 critical	
upper	 treatment	 threshold	of	360µmol/L,	we	are	95%	confident	 that	 the	 result	 is	between	322.2	
and	 397.8µmol/L	 (i.e.	 360µmol/L	 ±10.5%).	 However,	 this	 concentration	 range	 does	 not	 include	
variability	due	to	the	pre-analytical	factors	such	as	difference	in	DBS	specimen	collection	techniques	
or	 the	 inherent	 differences	 between	 different	 laboratory	 test	methodologies.	 The	 inter-assay	 CV	
and	MU	for	the	plasma	assay	in	our	laboratory	is	3%	and	5.8%	(i.e.	1.96	x	3)	respectively.		
Understanding	the	variability	of	the	test	used	to	monitor	patients	serially	in	order	to	assess	optimal	
dietary	control	 is	also	 important	and	the	reference	change	value	(RCV)	can	be	used	to	determine	
this.	 	 The	RCV	 refers	 to	 the	minimum	critical	 difference	between	 two	 consecutive	 results,	 in	 the	
same	patient,	which	needs	to	be	exceeded	in	order	for	a	significant	change	to	have	occurred	(Fraser	
2009).	As	there	are	two	sets	of	phenylalanine	results	to	consider,	we	must	take	into	consideration	
two	 sets	 of	 variations	 that	 must	 be	 combined	 to	 produce	 the	 RCV.	 This	 combined	 variation	 is	
represented	by	the	following	equation:	
	RCV	=	2.77	x	  CVA
2
	+	CVI
2
	
	Where	 CVA	 =	 the	 analytical	 coefficient	 of	 variation	 (CV)	 of	 the	 test	 and	 CVI	 =	 within	 person	
biological	 variation.	 The	 CVI	 of	 phenylalanine	 in	 healthy	 adult	 individuals	 is	 9.5%	 (Corte	&	Venta	
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2010)	and	the	CVA	 (SJM	–	 laboratory)	for	a	DBS	phenylalanine	QC	is	5.3%.	The	two	sets	of	results	
being	compared	need	to	be	greater	than	2.77	(i.e.	√2	x	1.96)	times	the	analytical	and	within-person	
biological	 variations.	 The	 calculated	 RCV	 for	 phenylalanine	 using	 DBS	 specimens	 is	 30.2%.	
Therefore,	 for	 a	 patient	 with	 a	 DBS	 phenylalanine	 concentration	 of	 360µmol/L,	 an	 increase	 or	
decrease	 of	 >109µmol/L,	 would	 have	 to	 occur	 before	 the	 results	 are	 considered	 significantly	
different	(95%	confidence)	i.e.	not	due	to	the	within-person	biological	variation	or	test	variation.			
It	could	be	argued	that	including	the	effect	of	biological	variation	within	the	RCV	calculation	is	not	
applicable	as	PKU	patients	are	prescribed	a	specialist	diet	and	supplements	in	a	manner	to	maintain	
stable	phenylalanine	concentrations	throughout	the	day	(MacDonald	et	al	1996;	van	Spronsen	et	al	
2017).	 Furthermore,	 patients	 are	 advised	 to	 collect	 specimens	 at	 the	 same	 time	 of	 day,	 usually	
fasting	 in	 the	morning,	when	 the	phenylalanine	concentration	 is	highest	 (MacDonald	et	al	1996).	
Therefore,	assuming	optimal	compliance	with	this	regimen,	the	use	of	the	RCV	calculation	may	not	
be	an	appropriate	approach	to	assess	serial	changes	in	phenylalanine	concentrations	in	a	patient,	as	
only	large	variations	may	be	deemed	as	a	significant	change.	An	alternative	approach	to	calculate	
the	 critical	 difference	 between	 two	 patient	 results	 would	 be	 to	 remove	 the	 contribution	 of	 the	
within-person	 biological	 variation.	 This	 can	 be	 calculated	 by	 multiplying	 the	 assay	 imprecision	
(5.3%)	 by	 2.77	 which	 equals	 14.7%.	 Therefore	 at	 a	 concentration	 of	 360µmol/L,	 an	 increase	 or	
decrease	of	>52.9µmol/L	in	consecutive	DBS	specimens	would	be	considered	significant.	However,	
it	should	be	noted	that	the	MU	and	RCV	calculations	do	not	take	into	account	the	test	bias.	The	RCV	
value	using	plasma	test	results	is	27.6%	and	8.3%	(i.e.	2.77	x	3%)	when	the	contribution	of	biological	
variation	is	removed.		
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Analytical	test	bias	(Inaccuracy)	
Test	bias	refers	to	the	difference	between	the	test	result	obtained	and	the	reference	or	‘true’	value.	
Clinical	laboratories	compare	their	analytical	performance	with	results	from	EQA	schemes	(Table	2).	
In	 an	 attempt	 to	 define	what	 the	 acceptable	 test	 bias	 of	 phenylalanine	 should	be,	 the	biological	
variation	of	phenylalanine	can	be	used	to	derive	the	acceptable	bias,	and	this	has	been	calculated	
to	be	10.4%	(Corte	&	Venta	2010).	Furthermore,	the	Horwitz	equation	can	also	be	used	to	predict	
inter-laboratory	 variation	 on	 the	 basis	 of	 analyte	 concentration	 alone,	 as	 it	 is	 independent	 of	
method,	 specimen	 matrix	 and	 analyte.	 The	 Horwitz	 equation	 (%)	 =	 2C
-0.15
,	 where	 C	 is	 the	
concentration	 of	 the	 analyte,	 expressed	 as	 a	 mass	 fraction	 (Horwitz	 &	 Albert	 2006).	 For	
phenylalanine	 in	the	concentration	range	of	10	–	500µmol/L,	 this	would	equate	to	a	target	 inter-
laboratory	 variation	 of	 approximately	 10%.	 It	 is	 clear	 that	 the	 plasma	 tests	 conform	 to	 this	
calculated	acceptable	bias	of	10%,	whereas	the	DBS	tests	are	highly	variable	depending	on	the	EQA	
scheme	(Table	2)	and	this	is	in	part	due	to	the	fact	that	there	is	no	CRM	commercially	available	for	
DBS	 phenylalanine	 tests.	 	 Interestingly,	 the	 target	 test	 bias	 of	 10.4%	 derived	 from	 biological	
variation	is	similar	to	that	of	10%	calculated	using	the	Horwitz	formulae:	
The	UK	National	External	Quality	Assessment	Service	(NEQAS)	and	the	Centers	for	Disease	Control	
and	Prevention	(CDC)	schemes	have	been	available	for	many	years	and	are	intended	to	assess	the	
performance	of	the	newborn	screening	programmes.	More	recently	ERNDIM	has	introduced	a	DBS	
scheme	 targeted	 towards	 an	 assessment	 of	 control	 in	 patients	 receiving	 treatment.	 The	 pilot	
scheme	was	operational	 in	2017	and	2018	and	supplied	79	 laboratories	with	 four	DBS	specimens	
(phenylalanine	 range	 120	 to	 940µmol/L)	 and	 a	 DBS	 phenylalanine	 calibrator	 (350µmol/L).	
Laboratories	were	 asked	 to	 submit	 results	 from	both	 the	DBS	 specimens	 and	 the	DBS	 calibrator.	
Results	 from	 the	 four	 specimens	 were	 then	 virtually	 “calibrated”	 for	 each	 laboratory	 using	 the	
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standard	 material.	 The	 inter-laboratory	 CVs	 from	 the	 “raw”	 and	 the	 “calibrated”	 results	 were	
calculated	 for	 the	 four	 specimens	 (Table	 3).	 It	 can	 be	 seen	 that	 the	mean	 inter-laboratory	 CV	 is	
improved	 by	 the	 use	 of	 this	 virtual	 standard	 from	 20%	 using	 the	 “raw”	 data	 to	 10%	 when	 the	
“calibrated”	data	 is	 analysed.	 	 This	effect	 is	 evident	at	all	 concentrations	 from	120	 to	940µmol/L	
(Bonham	&	Weykamp	2018).	Effectively,	inter-laboratory	variation	could	be	reduced	significantly	by	
introducing	a	common	DBS	calibrator.	In	order	to	address	the	issues	regarding	the	inter-laboratory	
biases	observed	between	newborn	screening	 laboratories,	a	European	working	calibrator	 for	DBS	
phenylalanine	 (EWS-Phe-01)	 was	 created	 (Dhondt	 et	 al	 1998)	 and	 this	 is	 now	 produced	 by	 the	
International	 Society	 for	Newborn	 Screening.	 A	multi-analyte	 DBS	 amino	 acid	 reference	material	
has	also	been	produced	by	the	CDC	in	the	US	(Chace	et	al	1999).	However,	these	materials	are	only	
available	in	limited	quantities	to	kit	manufacturers	and	EQA	scheme	organisers.	
Reporting	inaccurate	monitoring	results	could	have	profound	effects	in	that	patients	may	be	falsely	
reassured	with	 lower	 results,	where	 laboratories	have	a	negative	bias	 for	DBS	phenylalanine	and	
conversely,	 those	 laboratories	 with	 a	 positive	 bias	 providing	 falsely	 elevated	 results	 which	 may	
prompt	a	stricter	dietary	regimen,	which	may	lead	to	non-compliance	issues.	Therefore,	with	such	
large	 and	 variable	 biases	 for	 DBS	 phenylalanine	 results	 being	 observed	 between	 different	
laboratories,	 it	 is	 evident	 that	 consideration	 should	 be	 given	 to	 test	 bias	 when	 utilising	 the	
treatment-ranges.	
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Establishing	optimal	analytical	performance	targets	for	phenylalanine	tests	
Unfortunately,	 there	 is	not	a	 single	 simple	approach	 to	establishing	optimal	analytical	 targets	 for	
analytes	measured	in	the	clinical	laboratory	and	several	strategies	exist	(Kenny	et	al	1999).	The	total	
allowable	error	(TAE)	of	a	test	can	be	used	to	establish	performance	targets	for	a	test.	The	TAE	of	a	
test	 is	the	maximum	error	that	can	be	tolerated	for	a	test	before	 it	has	a	significant	 impact	upon	
clinical	decision	making.	TAE	is	not	based	on	the	performance	of	the	analytical	test	being	used,	but	
is	 dependent	 on	 the	 clinical	 use	 of	 the	 test	 result	 and	 the	 inherent	 biological	 variability	 of	 the	
analyte	 (Klee	 2010).	 TAE	 should	 be	 derived	 objectively	 from	 an	 analysis	 of	 studies	 assessing	 the	
clinical	impact	of	the	test	performance,	although	this	is	often	difficult	to	achieve.		
Other	 strategies	 include	 professional	 recommendations	 by	 expert	 groups	 or	 those	 derived	 from	
data	obtained	 from	biological	 variation.	 The	TAE	of	 18.2%	and	a	bias	of	 10.4%	 for	phenylalanine	
have	been	calculated	using	data	from	the	biological	variation	of	amino	acids	in	plasma	from	healthy	
adult	 subjects	 (Corte	 &	 Venta	 2010).	 The	 total	 error	 (TE)	 of	 the	 phenylalanine	 tests	 can	 be	
calculated	using	the	following	formulae:	
		 TE	=	Test	bias	+	(1.96	x	test	CV)	
Table	2	shows	the	TE	of	the	plasma	and	DBS	tests	 in	our	laboratories.	On	comparing	these	to	the	
TAE	of	18.2%,	it	would	suggest	that	the	plasma	phenylalanine	tests	are	clinically	fit	for	purpose	to	
monitor	 patients.	 Conversely,	 the	 performance	 of	 the	DBS	 tests	 is	 less	 consistent,	 depending	 on	
which	EQA	results	are	used	to	calculate	the	test	bias	(Table	2).		
	
To	date	no	study	has	derived	an	analytical	goal	from	studies	that	have	assessed	the	clinical	impact	
of	test	performance	on	clinical	outcomes	in	patients	with	PKU.	However,	 it	 is	possible	to	derive	a	
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TAE	 using	 clinical	 outcome	 studies.	 Data	 from	 a	 meta-analysis	 of	 17	 studies	 (n=432	 patients),	
demonstrated	a	threshold	effect	of	a	phenylalanine	concentration	>400µmol/L,	that	was	associated	
with	an	IQ	of	 less	than	85	in	patients	aged	<6	years	(Fonnesbeck	et	al	2013).	Furthermore,	 it	was	
also	 shown	 that	 those	patients	 (age	 range	8-13	years)	with	a	 lifetime	phenylalanine	>400µmol/L,	
did	 worse	 than	 those	 with	 a	 phenylalanine	 <400µmol/L	 in	 all	 tests	 assessing	 executive	 function	
(Leuzzi	et	al	2004).	It	is	therefore	imperative	that	laboratory	tests	must	be	able	to	distinguish	with	
confidence	between	a	test	result	of	360µmol/L	(upper-limit	of	the	target	treatment-range)	and	one	
of	 400µmol/L,	which	 is	 potentially	damaging.	 Therefore	 the	measurement	error	of	 the	 test	must	
not	exceed	the	difference	between	the	two	test	results	(i.e.	40	µmol/L),	which	relates	to	a	TAE	for	
the	test	of	11.1%	(i.e.	(40/360)	x	100).	This	is	significantly	lower	than	the	TAE	of	18.1%	derived	by	
biological	variation.	However,	it	is	recognised	that	using	biological	variation	to	derive	TAE	can	lead	
to	 over	 estimation	 (Oosterhuis	 et	 al	 2011).	 If	we	 look	 at	whether	 the	 test	 is	 able	 to	 confidently	
detect	a	change	between	360	and	300µmol/L,	the	TAE	would	be	16.7%	(i.e.	(60/360)	x	100),	which	
is	 closer	 to	 the	 TAE	of	 18.2%	derived	by	biological	 variation.	 Therefore,	when	 comparing	patient	
phenylalanine	test	 results	 to	 target	 treatment-ranges	we	must	understand	the	TE	of	 the	test	and	
whether	or	not	it	is	fit	for	purpose	i.e.	the	TE	of	the	test	used	should	ideally	be	less	than	the	TAE	of	
the	test.		
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Pre-analytical	factors	affecting	the	measurement	of	phenylalanine	in	DBS	
The	 size	 (i.e.	 volume	 of	 blood	 applied	 to	 the	 filter	 paper)	 and	 quality	 of	 the	 bloodspot	 has	 a	
significant	 impact	on	 the	 results	obtained.	Phenylalanine	concentrations	are	significantly	 lower	 in	
smaller	DBS	relative	to	 larger	DBS	specimens	(Hall	et	al	2015;	George	&	Moat	2016;	Lawson	et	al	
2016).	 If	 a	 liquid	 blood	 specimen,	 containing	 phenylalanine	 at	 a	 concentration	 of	 360µmol/L,	 is	
applied	 to	 filter	 paper	 in	 different	 volumes	 (10	 to	 100µL)	 the	mean	 concentration	 of	 the	 actual	
measured	phenylalanine	in	the	DBS	samples	(using	a	standard	3.2mm	sub-punch	for	analysis)	would	
vary	from	300µmol/L	in	the	10	µL	DBS	to	400µmol/L	in	the	100µL	DBS	(Figure	3).	If	the	effect	of	DBS	
size	 and	 the	MU	 of	 the	 test	 are	 combined,	 then	 the	 range	 of	 results	 that	 could	 be	 reasonably	
observed	 for	 a	 specimen	 with	 a	 concentration	 of	 360µmol/L	 is	 anything	 between	 269	 and	
442µmol/L.	 However,	 this	 does	 not	 take	 into	 consideration	 the	 effect	 of	 the	 variable	 biases	
observed	for	the	phenylalanine	results,	which	may	further	compound	these	pre-analytical	errors.	A	
comparable	 effect	 is	 also	 seen	 for	 tyrosine	 concentrations	 (George	&	Moat	 2016),	which	 can	 be	
simultaneously	measured	 in	 the	FIA-MS/MS	DBS	phenylalanine	assay,	and	 is	used	 to	monitor	 the	
nutritional	supplementation	of	tyrosine.		
Following	the	reported	evidence	that	small	and	poor	quality	DBS	specimens	produce	falsely	low	and	
erroneous	results	for	the	metabolites	used	for	newborn	screening	(George	&	Moat	2016;	Lawson	et	
al	2016),	UK	newborn	screening	guidelines	for	DBS	specimen	rejection/acceptance	were	developed.	
Several	 UK	metabolic	 laboratories	 also	 adopted	 these	 specimen	 acceptance/rejection	 criteria	 for	
DBS	 specimens	 received	 for	 monitoring	 of	 PKU	 patients.	 Prior	 to	 implementation,	 an	 audit	 was	
undertaken	to	assess	the	impact	on	the	DBS	monitoring	service.	It	was	demonstrated	in	one	of	the	
author’s	 laboratory	 (RSC)	 that	 if	 these	 criteria	 were	 applied	 to	 specimens	 received	 for	 PKU	
monitoring	over	a	4	week	period,	143	out	of	the	300	specimens	(47.7%)	received	would	have	been	
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rejected.	The	vast	majority	of	these	specimens	were	too	small	and	would	have	produced	significant	
negative	biases.	This	 finding	highlights	 the	 fact	 that	 the	negative	bias	observed	due	 to	 small	DBS	
and	the	lower	concentration	in	DBS	versus	plasma	specimens,	would	result	in	falsely	lower	results,	
thereby	giving	 false	re-assurances	as	to	optimal	metabolic	control	 in	patients.	Following	patient	/	
parent	training	for	the	collection	of	DBS	specimens	the	number	rejected	due	to	being	too	small	or	
poor	quality	reduced	to	26.2%.		
Filter	paper	 collection	devices	 for	 capillary	blood	collection	 from	heel	or	 finger	pricks	are	Class	 II	
Medical	Devices	(21	CFR	862.1675),	and	should	meet	international	criteria	for	performance	by	the	
Clinical	 &	 Laboratory	 Standards	 Institute	 (CLSI	 2013).	 The	 Newborn	 Screening	 Quality	 Assurance	
Program	at	CDC	conducts	voluntary	evaluations	of	all	 lots	of	Food	and	Drug	Administration	(FDA)-
registered	 collection	 devices	 before	 they	 are	 released	 to	 the	 user	 community	 for	 newborn	
screening	and	other	applications	 (Mei	et	al	 2001;	Mei	et	al	 2010).	 In	general,	 all	 filter	paper	 lots	
comply	with	CLSI	performance	criteria	(Mei	et	al	2010).		The	CLSI	provides	the	framework	for	filter	
paper	performance.	Because	filter	paper	is	a	natural	product	produced	from	cotton	linters,	defining	
how	the	matrix	influences	blood	collection	is	important	so	that	precision	and	reproducibility	can	be	
achieved	from	lot-to-lot	(Mei	2010).	These	 international	standardization	efforts	ensure	uniformity	
of	specimen	collection,	calibrators,	QC	and	reference	materials	for	newborn	screening	assays.	Using	
DBS	specimens	for	patient	monitoring	adds	additional	requirements	for	the	precision	and	accuracy	
of	 analyte	 recovery.	 The	 type	 of	matrix	 used	 for	 calibration	 and	 QC	materials	 will	 influence	 the	
analyte	 recovery.	 Ideally,	methods	 testing	patient	DBS	specimens	should	also	use	DBS	calibration	
and	QC	to	correct	for	the	filter	paper	matrix.	
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Discussion	and	Recommendations	
Although	 the	 difference	 between	 DBS	 and	 plasma	 phenylalanine	 concentrations	 in	 paired	
specimens	has	previously	been	reported,	the	clinical	impact	on	patient	management	has	not	been	
assessed.	A	DBS	 result	 compared	 to	 a	 plasma	 target	 treatment-range	 could	 be	 falsely	 reassuring	
and	 potentially	 damaging,	 particularly	 in	 those	 laboratories	 where	 large	 negative	 biases	 are	
observed	 for	 DBS	 concentrations.	 To	 provide	 comparable	 results	 for	 patient	 monitoring,	 a	
calibration	factor	could	be	used	to	report	DBS	results	as	plasma	equivalents	to	ensure	meaningful	
comparison	of	results	to	the	recommended	target	treatment-ranges.	This	is	preferable	to	reporting	
patient	 results	 against	 different	 target	 treatment-ranges	 as	 this	 may	 cause	 confusion	 for	 both	
patients	 and	 clinicians.	 However,	 it	 is	 essential	 that	 the	 patient	 DBS	 specimens	 collected	 are	 of	
adequate	 size	 and	 quality	 to	 ensure	 accurate	 results,	 because	 the	 differences	 between	DBS	 and	
plasma	 specimens	 are	more	 variable	when	 patients	 apply	 their	 own	 blood	 onto	 the	 filter	 paper	
collection	 devices	 compared	 to	 those	 applied	 by	 trained	 healthcare	 professionals	 (Stroup	 et	 al	
2016).	 Improvement	 in	 DBS	 specimen	 quality	 could	 be	 potentially	 achieved	 by	 the	 use	 of	 blood	
collection	 devices,	 that	 collect	 defined	 volumes	 of	 liquid	 blood	 for	 sampling	 (Lenk	 et	 al	 2015;	
Leuthold	et	al	2015;	Neto	et	al	2018;	Spooner	et	al	2015)	and	such	devices	should	be	evaluated	in	
order	 to	 improve	 the	 biochemical	 monitoring	 of	 patients.	 It	 has	 been	 highlighted	 that	 the	
development	of	point-of-care	devices	to	measure	liquid	whole	blood	phenylalanine	concentrations	
in	the	patient’s	home	would	optimise	outcomes	as	a	result	of	shorter	turnaround	times	for	results	
(Camp	 et	 al	 2014;	 van	 Spronsen	 et	 al	 2017).	 However,	 until	 the	 issue	 of	 test	 calibration	 and	
alignment	between	plasma	and	DBS	specimens	has	been	addressed,	caution	should	be	taken	before	
adopting	such	technology.		
Recently,	 Sapropterin	 dihydrochloride	 (Kuvan®),	 a	 synthetic	 form	 of	 the	 tetrahydrobiopterin	
cofactor	 for	phenylalanine	hydroxylase,	 has	been	used	 successfully	 to	 lower	blood	phenylalanine	
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concentrations.	 A	 30%	 reduction	 is	 defined	 as	 being	 responsive	 to	 therapy	 (Burton	 et	 al	 2007).	
Furthermore,	lesser	reductions	of	10-20%	may	represent	clinically	meaningful	outcomes	(Burton	et	
al	2007).	However,	detecting	changes	in	phenylalanine	concentrations	of	10-20%	using	DBS	samples	
will	 be	 challenging	 due	 to	 the	 issues	 outlined.	 It	 is	 advisable	 that	 plasma	 phenylalanine	
measurements	are	used	to	determine	the	response	to	Sapropterin	therapy.		
	
The	impact	of	the	differences	in	phenylalanine	results	obtained	from	different	specimen	types	and	
laboratory	 instruments	on	patient	management	using	 the	 recommended	target	 treatment-ranges	
needs	 to	 be	 reviewed	 and	 guidance	 provided	 in	 future	 recommendations.	 In	 addition,	 future	
guidelines	should	include	criteria	for	phenylalanine	test	performance	and	ensure	traceability	of	the	
method/calibration	used,	including	the	use	of	the	DBS	calibration	and	control	materials.	No	study	to	
date	has	derived	an	analytical	goal	by	assessing	the	clinical	 impact	of	test	performance	on	clinical	
outcomes	in	patients	with	PKU.	The	TAE	of	the	test	is	a	useful	goal,	as	this	indicates	the	maximum	
error	that	can	be	tolerated	before	it	has	a	significant	effect	on	patient	management.	However,	the	
use	 of	 accurate	 data	 from	 published	 studies	 to	 derive	 a	 TAE	 will	 be	 limited	 as	many	 state	 that	
‘blood’	 phenylalanine	 was	 measured	 and	 do	 not	 state	 whether	 plasma	 or	 DBS	 specimens	 were	
used.	 Furthermore,	 reference	 to	 the	 laboratory	 instrumentation	 used	 to	 quantify	 the	 ‘blood’	
phenylalanine	 is	 rarely	 provided.	 This	 lack	 of	 detail	 of	 specimen	 type,	 test	 methodology	 and	
calibrator	 traceability	 used	 will	 impede	 and	 potentially	 weaken	 future	 clinical	 studies	 aimed	 at	
deriving	TAE	and	meta-analyses	assessing	optimal	target	ranges	(both	upper	and	lower)	to	prevent	
adverse	outcomes.	
The	results	from	the	ERNDIM	EQA	pilot	scheme	in	2017	and	2018	indicate	that	there	are	significant	
problems	with	assay	calibration	resulting	in	an	unwanted	level	of	inter-laboratory	variation	and	an	
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inherent	 results	 bias	 in	 some	 laboratories.	 This	makes	 European/International	 recommendations	
relating	 to	 target	 treatment-ranges	 difficult	 to	 implement.	 The	 development	 of	 a	 commercially	
available	 CRM	 to	 standardise	 DBS	 phenylalanine	 tests	 is	 essential	 to	 address	 these	 issues.	 An	
international	effort	between	professional	 societies,	 expert	 scientific	 advisory	groups,	PKU	patient	
advocacy	 groups	 and	 organisations	 that	 have	 the	 expertise	 and	 capabilities	 to	 produce	 CRM	
material	is	required,	in	order	to	standardise	tests.		
Clinicians	 should	 take	 into	 consideration	 the	 effect	 of	 the	 test	 variability	 and	 bias	 (i.e.	 TE	 of	 the	
test),	 DBS	 size	 and	 quality	 in	 order	 to	 prevent	 over-interpretation	 of	 changes	 in	 phenylalanine	
concentrations,	 thereby	 preventing	 false	 re-assurances	 as	 to	 optimal	 dietary	 compliance.	 Clinical	
laboratories	undertaking	the	analysis	of	DBS	for	monitoring	of	PKU	patients	should	ensure	that:	[1]	
standardised	 criteria	 for	 the	 acceptance/rejection	 of	 specimens	 is	 implemented	with	 the	 aim	 of	
improving	the	quality	of	DBS	for	monitoring;	[2]	FIA-MS/MS	methods	are	replaced	with	LC-MS/MS	
methods	 to	 improve	 analytical	 performance;	 and	 [3]	 a	 rigorous	 evaluation	 of	 the	 bias	 between	
plasma	and	DBS	phenylalanine	results	is	undertaken	in	laboratories	to	derive	a	calibration	factor	in	
order	to	report	DBS	results	as	plasma	equivalents	 (ideally	on	an	 individual	patient	basis),	 thereby	
ensuring	meaningful	comparison	of	patient	results	to	the	recommended	target	treatment-ranges.	
This	is	of	paramount	importance	especially	in	the	context	of	those	infants	that	may	be	the	subject	
of	safeguarding	measures	as	a	result	of	phenylalanine	concentrations	that	are	persistently	outside	
the	 target	 treatment-ranges,	 and	 the	MU	of	 the	phenylalanine	 test	 result	 should	be	provided	 to	
guide	clinicians	and	dieticians	to	allow	a	more	objective	 interpretation	of	the	monitoring	of	serial	
results.	 Finally,	 patients	 and	 parents/carers	 should	 receive	 regular	 training	 on	 blood	 collection	
techniques	to	ensure	that	more	accurate	and	less	variable	results	are	obtained	in	order	to	achieve	
optimal	dietary	control	thereby	reducing	adverse	neurological	outcomes.	
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	Table	1.	Studies	assessing	the	differences	between	plasma,	DBS	and	whole	blood	
phenylalanine	concentrations	using	a	variety	of	laboratory	technologies.	
	
Plasma	
assay	
DBS	assay	 Bias																									
DBS	vs	Plasma		
Source	
IEC	 FIA-MS/MS	 -19%	 Gregory	et	al	2007	
IEC	 FIA-MS/MS	 -28%	 Grunert	et	al	2013	
IEC	 FIA-MS/MS	 -26%	 Groselj	et	al	2015	
IEC	 FIA-MS/MS	 -28%	 Stroup	et	al	2016	
IEC	 FIA-MS/MS	 -18%	 Present	study	
IEC	 HPLC	 -19%	 Gregory	et	al	2007	
IEC	 IEC	 -15%	 Stroup	et	al	2016	
Plasma	
assay	
Whole	blood	
assay	
Bias	-	whole	blood	vs	
Plasma		
	
IEC	 IEC	 -7.5%	 Hagenfeldt	&	Arvidsson	1980	
HPLC	 HPLC	 -	8%	 Mo	et	al	2013	
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Table	 2	 	 Analytical	 performance	 of	 the	 plasma	 and	 DBS	 tests	 in	 our	 laboratories	 against	 the	
various	EQA	schemes.		
Sample	Type	 Test	imprecision	
(CVA)	%	
Test	Bias	%	 TE	of	test	%	
Laboratory	1	 	 	 	
Plasma	 3.0	 1.6
a
	 7.5	
Plasma	 3.0	 3.7
b
	 9.6	
DBS	 5.3	 8
c
	 18.4	
DBS	 5.3	 11.1
d
	 21.5	
DBS	 5.3	 16
e
	 26.4	
	 	 	 	
Laboratory	2	 	 	 	
Plasma	 2.0	 4.6
a
	 8.5	
Plasma	 2.0	 2.1
b
	 6.0	
DBS	 5.1	 2.9
c
	 12.9	
DBS	 5.1	 18.2
d
	 28.2	
DBS	 5.1	 2.7
e
	 12.7	
	
Test	bias	was	calculated	using	the	all	laboratory	mean	for	the	participants	using	the	following	EQA	
schemes;	
a
UK	 NEQAS	 quantitative	 amino	 acids,	
b
ERNDIM	 plasma	 amino	 acids,	
c
UK	 NEQAS	 DBS	
newborn	 screening,	
d
ERNDIM	 –	DBS	monitoring	 (Pilot	 scheme),	
e
CDC	 –	DBS	Newborn	 Screening.	
DBS	phenylalanine	measured	by	FIA-MS/MS	in	both	laboratories,	plasma	phenylalanine	measured	
by	IEC	in	both	laboratories.		TE	is	the	total	error	of	the	test	and	is	calculated	as	TE	=	Test	bias	+	(1.96	
x	test	imprecision	(CVA)).	
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Table	3	 	 Inter-laboratory	variation	(expressed	as	CV%)	with	and	without	calibration	using	a	DBS	
standard	in	79	laboratories	
	
Parameter	 Sample	1	 Sample	2	 Sample	3	 Sample	4	 Mean	
Phenylalanine	concentration	(µmol/L)	 120	 330	 420	 940	 452	
Inter-laboratory	CV	without	calibration	 23%	 20%	 18%	 20%	 20%	
Inter-laboratory	CV	with	calibration	 14%	 9%	 8%	 9%	 10%	
	
 
